new developments in uterine cancer - igcs · 2015;33(31):3576-3582. slomovitz bm, et al. cancer....
TRANSCRIPT
![Page 1: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/1.jpg)
New Developments in Uterine Cancer
Matthew A. Powell, MD Professor & Chief Division Gyn Oncology
Washington University School of Medicine
St. Louis, Missouri, USA
![Page 2: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/2.jpg)
How do we improve? Targets: • Anti-Angiogenesis• EGRF• mTOR/PI3K/AKT• DNA repair• Immunotherapy• Combinations
![Page 3: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/3.jpg)
![Page 4: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/4.jpg)
Drug N RR SD PFS> 6 Months PFS
mTOR inhibitors Temsirolimus (Oza 2011) Chemo-naïve 29 14% 69% - 7.3 months
Chemo-treated 25 4% 48% - 3.2 months
Ridaforolimus (Tsoref 2014) 31a 8.8% 52.9% - -
Ridaforolimus vs progestin or investigator choice chemotherapy (Oza 2015)
64 vs 66 4.6% vs
3% 56.3 vs 27.7 (P = .003) -
5.6 months vs 1.9 months
(HR, 0.39; 95% CI, 0.23 to 0.66;
P<.001)
Everolimus (Slomovitz 2010) 28 0% 43% - -
PI3K inhibitors Pilasarilib (XL147) (Matulonis 2014) 67 6% 37.3% 11.9% -
BKM120 NCT01289041 71 2.8% 36% - 1.9 months
Oza AM, et al. J Clin Oncol. 2011;29(24):3278-3285. Tsoref D, et al. Gynecol Oncol. 2014;135(2):184-189. Oza AM, et al. J Clin Oncol. 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol.
Courtesy Minig L and Romero I (In press)
Phase II Clinical Trials With mTOR and PI3K Family in Women With Endometrial Cancer
![Page 5: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/5.jpg)
GOG 3007
![Page 6: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/6.jpg)
Progression-Free and Overall Survival by regimen
PFS by Regimen Overall Survival by Regimen
![Page 7: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/7.jpg)
PFS by prior treatment
![Page 8: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/8.jpg)
No prior chemotherapy
Regimen RR PFS
Everolimus/letrozole 53% 21.6 months
Tamoxifen/MA 43% 6.1 months
Carboplatin/paclitaxel 51% 14 months
![Page 9: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/9.jpg)
Future Directions???: GOG-189: Chemo v. Hormones
Stage III & IV, Recurrent Any histology
R A N D O M I Z E
Chemotherapy • Doxorubicin 45 mg/m2
• Cisplatin 50 mg/m2
• Paclitaxel (3 hr) 160mg/m2
Hormones • Megace 80 po BID• Tamoxifen 20 BID• Alternating 3 wks
P R O G R E S S I
O N Opened: 5-7-01
Closed: 8-9-02 Accrual: 42 (NNT = 630)
![Page 10: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/10.jpg)
Eligibility: • Stage III or IVA EC
measurable disease• Stage IVB or recurrent EC
(whether there is measurable disease or not)
• No prior chemotherapy
GOG#0286B
Arm 1: Paclitaxel 175 mg/m2 IV over 3 hours day 1 Carboplatin AUC = 5 IV day 1 Metformin 850 mg oral QD, beginning on day 1. If tolerated for 4 weeks, the dose will be increased to metformin 850 mg BID. Maintenance regimen: Metformin 850 mg oral BID until disease progression or prohibition of further therapy.
Arm 2: Paclitaxel 175 mg/m2 IV over 3 hours day 1 Carboplatin AUC = 5 IV day 1 Placebo for Metformin 850 mg oral QD, beginning on day 1. If tolerated for 4 weeks, the dose will be increased to placebo for metformin 850 mg BID. Maintenance regimen: Matched placebo oral until disease progression or prohibition of further therapy
• Phase II/III• N = 240/300 patients
(500 patients)• 1º Endpoint: PFS/OS
GOG 286B: Metformin Study (Stopped for Futility)
6 ADDITIONAL STUDIES IN PROGRESS PtIhe: Vraicpytori. a Bae-Jump, M.D. PhDOpen: 17 March 2014 ClinicalTrials.gov Identifier: NCT02065687
![Page 11: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/11.jpg)
![Page 12: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/12.jpg)
How do we improve? Targets: • Anti-Angiogenesis• EGRF• mTOR/PI3K/AKT• DNA repair• Immunotherapy• Combinations
![Page 13: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/13.jpg)
DNA Repair Pathways Endometrial Cancer & MSI+ (Ovary, Cervix)
• Microsatellite instability (oftenreferred to as MSI) is thehallmark of tumors withdefective MMR
• HRD has also been reported inendometrial cancers, with thehighest frequency in seroustype, TP53-mutated tumors
• Loss of MRE11, a proteininvolved in DSB repair, hasbeen reported in ~30% ofendometrial cancers
• Cervical Cancer. MSI occurs inabout 5+% of cervical cancers(Ercoli, Roa, Wong)
MSI in endometrial cancer
• Lynch syndrome, which is caused by inherited dMMR, accounts for 2%–5%of all cases1,8
• MSI also occurs in sporadic cases and is primarily attributed to MLH1 promoter hypermethylation & POLE mutants9;
SGO recommen ds all women with endometrial cancer undergo Lynch syndrome screening and/or molecular testing10
of endometrial cancers are classified as MSI+2
~20%
Ovary Sub-type Defective MMRt (%)
HGS 0.9
LGS 4.2
Endo 7.1
CC 2 Mucinous 0
(Xioa et al)
![Page 14: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/14.jpg)
Email questions to Dr. Wendel Naumann at [email protected] for discussion during the break.
• A Randomized Phase II Study Comparing Single-Agent Olaparib, SingleAgent Cediranib, and the Combination of Cediranib/Olaparib inWomen with Recurrent, Persistent or Metastatic Endometrial Cancer(Mackay/Bender/Rimel)
• N=120 (40/arm). Stat: Filiaci
![Page 15: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/15.jpg)
How do we improve? Targets: • Anti-Angiogenesis• EGRF• mTOR/PI3K/AKT• Immunotherapy:• DNA repair• Combinations
![Page 16: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/16.jpg)
Endometrial Cancer (EC) – Four molecular subtypes<br />(Integrated genomic, transcriptomic and proteomic characterization)
GOG 210 Endometrioid (Cosgrove 2018)
Incidence: 49% CNS, 4% POLE mutant, 39% MMR deficient, 8% copy number altered (CNA). Cancer-specific mortality: 5%=CNS ; 2.6% =POLE tumors; 7.6%=MMR deficient tumors; 19% with CNA tumors.
![Page 17: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/17.jpg)
questions t endel N
1. Fader AN, et al. Presented at SGO, 2016. 2. Ott PA, et al. J Clin Oncol. 2017;35(22):2535-41. 3. Fleming GF, et al.Presented at ASCO Annual Meeting, 2017. Abstract 5585. 4. Makker V, et al. Presented at ASCO Annual Meeting, 2018. Abstract 5596. 5. Oaknin A, et al. Presented at ESMO, 2018. Abstract 935PD. 6. Pembrolizumab package insert. Merck & Co, Inc; December 2018.
Fader et al. Pooled MSI-H
Endometrial Cancer: Immunotherapy
KEYNOTE-0282 NCT01375842
3NCT02501096
4 GARNET5
Phase(s) 2 1 and 2 1b 1a 1b/2 1/2
Population Previously treated dMMR-
recurrent or persistent EC
Previously treated MSI-H/dMMR ECb
Previously treated locally advanced or metastatic PD-
L1+ EC
Recurrent EC Advanced EC
Previously treated
recurrent/advanced MSI-H
EC
Patients, n 9 14 24 15 54 35
Treatment Pembrolizumab Pembrolizumab Pembrolizumab Atezolizumab Pembrolizumab + lenvatinib
Dostarlimab
ORR, % 56a 36a 13.0a 13 36.7 49 & 20DCR, % 89 — 26.0 27 — 64
DOR — 4.2+–17.3+ moa
— — NR NR
mPFS — — 1.8 mo 1.7 mo 10.1 mo —
mOS NR — NR 9.6 mo — —
Safety summary No AEs >Gr 3 Per label ≥Gr 3 TRAEs:
16.7% Any TRAE:
47% ≥Gr 3 TRAEs:
59% ≥Gr 3 TRAEs:
11.4%
Median follow-up 9.1 mo o 4.0 mo —
![Page 18: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/18.jpg)
GYY-020
• Randomized phase III trial of radiation +/- checkpointinhibitor for high intermediate risk mismatch repairdeficient (dMMR) endometrioid endometrial cancer(Backes)
• N: 168
![Page 19: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/19.jpg)
How do we improve? Targets: • Anti-Angiogenesis• EGRF• mTOR/PI3K/AKT• Immunotherapy• DNA repair• Combinations
![Page 20: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/20.jpg)
Randomized phase II/III study of carboplatin + paclitaxel vs. carboplatin + paclitaxel + pembrolizumab in patients with advanced stage (stage 3 or 4) or
recurrent endometrial cancer
Stage III & IV or recurrent endometrial cancer
(Stage 3 or 4A: measurable disease; Stage 4B or recurrent whether there is
measurable disease or not)
MMR-proficient vs. MMR-deficient
R
C/T + placebo
C/T + pembrolizumab + maintenance pembrolizumab
x 12 months
Stratification factors: MMR-proficient vs. MMR-deficient, performance status, measurable disease status
N=590 pMMR patients N=185 deficient MMR (dMMR)
Patients may have received prior radiation therapy or hormonal therapy. Patients in whom both radiation and chemotherapy are planned must receive radiation prior to entry on study. C = Carboplatin; T = Paclitaxel
![Page 21: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/21.jpg)
Stage III & IV or recurrent endometrial cancer
(Stage 3 or 4A: measurable disease; Stage 4B or recurrent whether there
is measurable disease or not) ALLOW CSRCINOSARCOMAS
MMR-proficient vs. MMR-deficient
R
C/T + placebo
C/T + Dostarlimab + maintenance
Dostarlimab x 12 months
A Phase 3, randomized, double-blind, multicenter study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in patients with reurrent or primary advanced endometrial cancer
GOG=Partners / ENGOT-EN6 / NSGO
![Page 22: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/22.jpg)
Email questions to Dr. Wendel Naumann at [email protected] for discussion during the break.
Hot & Cold: AMANDA Study design
Stra?fiedby§ PriorRT§ Recurrentdisease§ MSI
PrimaryEndpoint:OSandPFS
SecondaryEndpoints:PFSinMSI,PFS2,RR,QoL,safety
Transla?onal Endpoints: PD1, PDL1, TILs, blood basedbiomarkers
StudyDura?on:accrual2years;Follow-up:2years
Atezolizumab\Placebowillbeadministered:- asI.V.infusionevery21days- unQl progression confirmed at least 4 weeks aTer the firstevidenceofprogressionaccordingtoRECISTv1.1.
Paclitaxel 175mg/m2 carboplatin AUC 5 or 6
placebo
Maintenance placebo
Paclitaxel 175mg/m2 carboplatin AUC 5 or 6 atezolizumab 1200mg
Maintenance atezo 1200mg
Stage III/IV or recurrent
endometrial cancer
Confirmed PD
R 1:2
![Page 23: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/23.jpg)
• Dynamic time in endometrial cancer therapeutics
• Multiple studies exploring the utility of IO in the front line andrecurrent settings
• Aside from MSI-H/dMMR (and TMB) no defined biomarkers
Conclusions
Pembrolizumab Avelumab Atezolizumab Cemiplimab Durvalumab Nivolumab
?
• AtTEnd/MaNGO
• Avelumabsingle agent
• Durvalumab single agent or+ olaparib
?
Dostarlimab
• Single agent(dMMR/pMMR)
• C/T + TSR-042• Lenvatinib +
Pembrolizumab• C/T + pembrolizumab
![Page 24: New Developments in Uterine Cancer - IGCS · 2015;33(31):3576-3582. Slomovitz BM, et al. Cancer. 2010;116(23):5415-5419. Matulonis U, et al. Gynecol Oncol. Courtesy Minig L and Romero](https://reader034.vdocuments.site/reader034/viewer/2022043019/5f3ba5a8590ff5151b7f4c93/html5/thumbnails/24.jpg)
Key Clinical Studies in Advanced, Recurrent, or Metastatic Endometrial Cancer
Ongoing Phase 3 Trials for Systemic Therapy in Advanced, Recurrent, or Metastatic Endometria l Cancer
Merck: GY018 (1L), pembrolizumab/ chemotherapy
Merck: KEYTRUDA monotherapy tumor-
agnostic FDA approval, MSI-H
Merck/Eisai: KEYNOTE-146, pembrolizumab/
lenvatinib, MSI-H/non-MSI-H
Tesaro/GSK: GARNET,
dostarlimab monotherapy,
MSI-H/non-MSI-H
Tesaro/GSK: RUBY,
dostarlimab/ chemotherapy
Merck/Eisai: KEYNOTE-775
(Ph3), pembrolizumab/
lenvatinib
AstraZeneca: DOMEC,
durvalumab/olaparib
Genentech/Roche: ATEnd,
Atezolizumab/ chemotherapy
Merck/Eisai: LEAP-001 (1L),
pembrolizumab/ lenvatinib
2023 … 2021 2014 2020 2022 2024